A Trial of Academic Detailing to Promote Prescribing of Biosimilars

Running, not enrolling · Not applicable

Conditions studied: Autoimmune Diseases, Rheumatoid Arthritis (RA), Inflammatory Bowel Disease (IBD), Psoriasis (PsO)

In brief

The goal of this trial is to learn if an interactive evidence-based educational outreach visits to clinicians who prescribe biologics change prescribing of biosimilar medications. The main questions it aims to answer are: 1. Do educational outreach visits lead to a higher number of prescriptions for biosimilar versions of adalimumab? 2. Do in-person or virtual visits work better? Researchers will compare clinicians offered the educational outreach visit to those who are not offered the visit to see if there is a difference in prescribing of biosimilar versions of adalimumab instead of the original brand-name version. Participants will be offered the chance to meet with a trained clinician who will provide educational information tailored to their knowledge and attitudes on the topic. They will also be provided an educational brochure and patient educational materials.

Key facts

Study ID

NCT07221890

Run by

Brigham and Women's Hospital

People needed

1325

Starts

2025-11-06

Expected to finish

2027-03-31

Last updated by the study team

2026-05-14

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Wrote 7 or more adalimumab prescriptions that were filled by patients enrolled in research-eligible Humana Medicare Part D plans in the calendar year 2025

You may not qualify if…

• Retired
• Not able to identify active clinical practice in the US (50 states plus Washington DC)

Where it is running

• Humana Healthcare Research, Inc. — Louisville, Kentucky, United States
• Brigham and Women's Hospital — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.